UK national guidelines on the management of syphilis 2008.

GUIDELINE TITLE
UK national guidelines on the management of syphilis 2008.
British Association for Sexual Health and HIV

BIBLIOGRAPHIC SOURCE(S)
Kingston M, French P, Goh B, Goold P, Higgins S, Sukthankar A, Stott C, Turner A, Tyler C, Young H, Syphilis Guidelines Revision Group 2008, Clinical Effectiveness Group. UK National guidelines on the management of syphilis 2008. Int J STD AIDS 2008 Nov;19(11):729-40. [142 references] PubMed

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates previous versions: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD). 2002 national guidelines on the management of early syphilis. London: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD); 2002. Various p. [94 references]

Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD). 2002 national guidelines for the management of late syphilis. London: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD); 2002. Various p. [22 references]

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

April 14, 2009 - Rocephin (ceftriaxone sodium): The U.S. Food and Drug Administration (FDA) notified healthcare professionals of an update to a previous alert that addresses the interaction of ceftriaxone with calcium-containing products, based on previously reported fatal cases in neonates. Based on the results from recent in vitro studies, FDA now recommends that ceftriaxone and calcium-containing products may be used concomitantly in patients >28 days of age, using the precautionary recommendations noted because the risk of precipitation is low in this population. FDA had previously recommended, but no longer recommends, that in all age groups ceftriaxone and calcium-containing products should not be administered within 48 hours of one another.

abrir aquí para acceder al documento NGC AHRQ completo:
UK national guidelines on the management of syphilis 2008.